Olema Oncology to Present at Upcoming Investor Conferences in November
November 01 2022 - 8:00AM
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the
“Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of targeted therapies for women’s cancers, today
announced that the Company will present at the following investor
conferences in November:
- Presentation at the
Credit Suisse 31st Annual Healthcare Conference at the Terranea
Resort in Rancho Palos Verdes, CA, on Wednesday, November 9, at
9:10 a.m. Pacific Time (12:10 p.m. Eastern Time)
- Fireside chat at the
Jefferies London Healthcare Conference at The Waldorf Hilton in
London, UK, on Wednesday, November 16, at 11:30 a.m. GMT (6:30 a.m.
Eastern Time)
- Virtual fireside
chat at the 5th Annual Evercore ISI HealthCONx Conference on
Tuesday, November 29, at 2:40 p.m. Eastern Time
Live webcasts of the presentations and any accompanying
presentation materials will be available under the Investors &
Media section of Olema’s website (www.olema.com) and will be
archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
targeted therapies for women’s cancers. Olema’s lead product
candidate, OP-1250, is a proprietary, orally-available small
molecule with dual activity as both a complete estrogen receptor
(ER) antagonist (CERAN) and a selective ER degrader (SERD). It is
currently being evaluated both as a single agent in an ongoing
Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors
(palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in
patients with recurrent, locally advanced or metastatic ER-positive
(ER+), human epidermal growth factor receptor 2-negative (HER2-)
breast cancer. OP-1250 has been granted FDA Fast Track designation.
Olema is headquartered in San Francisco and has operations in
Cambridge, Massachusetts.
IR Contact:Shane Kovacs, COO and CFOir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Sep 2023 to Sep 2024